The Public Sector is Poorly Suited to Developing New Drugs
Saturday, January 29th, 2011This past Tuesday, President Obama delivered the annual “State of the Union” message . His theme was “Winning the Future.” He correctly noted that a major component of winning the future is investment in research and development, the production of new technologies, new ways of doing things.
President Obama noted:
“The first step in winning the future is encouraging American innovation. None of us can predict with certainty what the next big industry will be or where the new jobs will come from. Thirty years ago, we couldn’t know that something called the Internet would lead to an economic revolution. What we can do — what America does better than anyone else — is spark the creativity and imagination of our people….
“Our free enterprise system is what drives innovation. But because it’s not always profitable for companies to invest in basic research, throughout our history, our government has provided cutting-edge scientists and inventors with the support that they need.”
President Obama correctly suggests that innovation, the development of new technology, is crucial for our society, for our economy, and that the profit motive is behind such innovation. He is also right in understanding that the profit incentive does not work well in providing the incentive for investment in basic research.
Economists have long made a distinction between goods that can be profitably produced and marketed to individual buyers and goods with benefits that are shared amongst the general public and cannot be sold through voluntary markets because once provided, others will free ride on those who provided the good in the first place. The first type of good, a private good , is like a sandwich—if one person buys that sandwich, he can consume it and that means less for others. Sellers of private goods can decline to provide their goods to those who are unwilling to pay for them. Private goods can be profitably sold in voluntary markets.
On the other hand, some goods have a shared consumption characteristic. For example, in a city, air quality is mostly shared. Protection from foreign invasion of military forces is a shared good as is protection from terrorists. If I am protected from terrorist attacks, so are those who are near me. This type of good, called a public good http://en.wikipedia.org/wiki/Public_goods, has benefits that cannot be denied to non-payers, not from some law, but because it is just too costly to do so.
Similarly, research is divided into several types, one of which is referred to as basic research (http://en.wikipedia.org/wiki/Basic_research) and another as applied research (http://en.wikipedia.org/wiki/Applied_research). Basic research delves into theories and generally cannot be kept from being used by others, but does not have immediate commercial use. Some applied research has immediate commercial use, while some applied research has a commercial use. Applied research is often patentable, while basic research is not. Basic research is a type of public good, while applied research is a private good.
These distinctions help us understand why universities, especially large research universities, have more of an emphasis on basic research, while companies do most of the applied research, developing patentable products. Private firms have what economists call a “comparative advantage” in producing private goods, because there is a profit to be made. Comparative advantage (http://en.wikipedia.org/wiki/Comparative_advantage) is about producing at a lower opportunity cost (http://en.wikipedia.org/wiki/Opportunity_cost) than others, and in this case, lower costs than other types of entities, such as governments and non-profit organizations.
A good example of the problem when tasks are inefficiently done, in other words, not done by those who can do them at least cost, not done according to what economists call “comparative advantage” would be to have a gifted athlete, such as New Orleans Saints star quarterback, Drew Brees, selling hot dogs in the stands at the games, rather than making spectacular plays on the field. He might be better at selling hot dogs than anyone else, but he is so much better at the quarterback position and so valued at that position, the Saints and their fans would be worse off if he sold hot dogs in the stands instead. (Be sure to read the Wikipedia definitions and explanations of these ideas that are given above in the provided links.)
Private for-profit firms, because of the profit incentive, enabled by the use of enabled by constitutionally mandated patents, are much better at applied research that involves product development than governments. The profit incentive induces profit-seekers to find ways of accomplishing things that are less costly. This includes finding lower cost ways of providing incentives to supplier operators, such as the scientists whom they employ.
Governmental entities, having no incentive to earn profits, and so, no incentive to cut costs, are ill-suited to developing products at a low cost. Just as President Obama noted in his “State of the Union” message, we cannot predict where the “next new thing” will be, and so, it is better left to entrepreneurs to develop new products. Public bodies, however, are better suited to financing basic research than for-profit firms, as firms will spend little time, effort and money on developing something that suffers from the free-rider problem.
So, what we see is that the development of new products is better carried out by private firms who have both the incentive to carry out this work at least cost and are better suited to risk-taking involved in deciding which research path to try, with many leading to dead ends, and only a few being profitable. On the other hand, basic research which results in general findings which usually have no immediate applications in profitable enterprises, but sometimes lead to a host of applications, is best financed by government because private firms are not able to keep others from using their basic research, as it is not patentable.
Imagine, then, the surprise of many when it was recently announced in this Gadiner Harris New York Times article that officials with the National Institutes of Health “have decided to start a billion-dollar government drug development center to help create medicines.”
The reason that the government should do invest in developing new patentable products, they claim, is because of the sharp slowdown in patent applications by pharmaceutical firms. They also claim that a billion dollars is a small initiative when it often takes a pharmaceutical firm a billion dollar investment in research to create just one new product.
If government experts cannot tell what the most promising area for research is, and if governments are ill-suited to developing new products, it seems that taking these funds out of other places, whether basic research or from private industry, such as the oil industry, as the President suggested as the place to get funds for his new research initiatives, and using them for government directed research into new products, is like taking Drew Brees off of the field and into the stands to hawk hot dogs.
What the Obama administration should ask before beginning this new quest into the drug development enterprise is “why have patent applications fallen so drastically from 2008 to now?” Two possible reasons should be obvious and should be examined. First, could it be that just as investment in other areas have dropped off because of the recession and the lack of confidence people have in the future, the same reluctance to invest may have hit the pharmaceutical industry. A second possibility that the administration may not want to believe, but, nonetheless should be examined, is that the push for health-care reform by the administration, with its likely impact on lower profitability of pharmaceuticals, may have reduced the incentive to invest in new drug development so much that patent applications fell. But whatever the reason, it should be clear that the government’s role in research is one of supporting basic research, while private industry is better suited to developing new products, such as new drugs. We will be in a better position to “Win the Future” if we have the players in the process in the roles for which they are best suited, where they have a comparative advantage.
-MC

